MedTrace Logo

A Pilot Trial of One-Day Accelerated TMS and D-cycloserine in Suicidal Patients With Borderline Personality Disorder

NCT07460947 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-04-28

No results posted yet for this study

Summary

This study tests a new treatment for people with borderline personality disorder (BPD). The treatment combines a medication called D-cycloserine with one day of transcranial magnetic stimulation (TMS).

The main questions it aims to answer are:

* How many participants complete the treatment?
* How do participants feel about the treatment?
* Does the treatment have neurophysiological changes on participants?
* Does the treatment improve BPD symptoms?
* Do the benefits last over time?

Participants will be asked to:

* Come to the clinic for interviews and testing
* Complete weekly questionnaires for 4 weeks before the treatment day
* Take D-cycloserine the night before treatment
* Attend one treatment day at the clinic. On that day, they may receive up to 20 short TMS sessions (each lasting 3 minutes and separated by 30 minutes). This visit may last up to 12 hours.
* Complete weekly questionnaires for 6 weeks after the treatment day.

Conditions

  • Borderline Personality Disorder (BPD)

Interventions

DEVICE

TMS

TMS will consist of 600 pulses of intermittent theta burst stimulation (iTBS), with 3-minute treatment sessions delivered up to 20 times every 30 minutes for a 12-hour protocol.

DRUG

D-Cycloserine (DCS)

Participants will be asked to take a single dose (250mg) of D-cycloserine the night before the treatment day.

Sponsors & Collaborators

  • Mclean Hospital

    lead OTHER

Principal Investigators

  • Jenna M Traynor, PhD · Mclean Hospital

  • Joshua Brown, MD, PhD · Mclean Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2027-06-30
Completion
2027-12-31
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07460947 on ClinicalTrials.gov